LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Elenco Azioni・Cytokinetics Inc

Cytokinetics Inc

Chiusa

SettoreSettore sanitario

78.56 1.88

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

75.51

Massimo

78.81

Metriche Chiave
By Trading Economics
Entrata	-23M -206M
Vendite	1.6M 19M
EPS	-1.67
Margine di Profitto	-1,064.485
Dipendenti	673
EBITDA	112K -180M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+29.73% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	1.9B 10B
Apertura precedente	76.68
Chiusura precedente	78.56

Notizie sul Sentiment di mercato

By Acuity

65%

35%

304 / 346 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

32.3 / 40.43 Supporto e resistenza

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 mag 2026, 22:44 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mag 2026, 22:27 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mag 2026, 22:12 UTC

Utili

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mag 2026, 21:52 UTC

Acquisizioni, Fusioni, Takeovers

LVMH to Sell Marc Jacobs

15 mag 2026, 00:00 UTC

Utili

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mag 2026, 23:57 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mag 2026, 23:56 UTC

Discorsi di Mercato

Gold Prices Rise on Strong Demand -- Market Talk

14 mag 2026, 23:56 UTC

Acquisizioni, Fusioni, Takeovers

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mag 2026, 23:47 UTC

Utili

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mag 2026, 23:47 UTC

Utili

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mag 2026, 23:46 UTC

Utili

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mag 2026, 23:28 UTC

Discorsi di Mercato

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mag 2026, 22:46 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 mag 2026, 22:35 UTC

Discorsi di Mercato

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mag 2026, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mag 2026, 22:06 UTC

Discorsi di Mercato

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mag 2026, 22:04 UTC

Utili

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mag 2026, 22:04 UTC

Utili

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mag 2026, 22:00 UTC

Utili

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q EPS 18c >NU

14 mag 2026, 21:55 UTC

Utili

Nu Holdings 1Q Rev $4.97B >NU

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

29.73% in crescita

Previsioni per 12 mesi

Media 100.18 USD 29.73%

Alto 140 USD

Basso 67 USD

Basato su 19 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

19 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 19 che hanno fornito valutazioni azionarie a Cytokinetics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

Recent bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

304 / 346 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.